Albumin in decompensated cirrhosis: new concepts and perspectives
Top Cited Papers
Open Access
- 26 February 2020
- Vol. 69 (6), 1127-1138
- https://doi.org/10.1136/gutjnl-2019-318843
Abstract
The pathophysiological background of decompensated cirrhosis is characterised by a systemic proinflammatory and pro-oxidant milieu that plays a major role in the development of multiorgan dysfunction. Such abnormality is mainly due to the systemic spread of bacteria and/or bacterial products from the gut and danger-associated molecular patterns from the diseased liver triggering the release of proinflammatory mediators by activating immune cells. The exacerbation of these processes underlies the development of acute-on-chronic liver failure. A further mechanism promoting multiorgan dysfunction and failure likely consists with a mitochondrial oxidative phosphorylation dysfunction responsible for systemic cellular energy crisis. The systemic proinflammatory and pro-oxidant state of patients with decompensated cirrhosis is also responsible for structural and functional changes in the albumin molecule, which spoil its pleiotropic non-oncotic properties such as antioxidant, scavenging, immune-modulating and endothelium protective functions. The knowledge of these abnormalities provides novel targets for mechanistic treatments. In this respect, the oncotic and non-oncotic properties of albumin make it a potential multitarget agent. This would expand the well-established indications to the use of albumin in decompensated cirrhosis, which mainly aim at improving effective volaemia or preventing its deterioration. Evidence has been recently provided that long-term albumin administration to patients with cirrhosis and ascites improves survival, prevents complications, eases the management of ascites and reduces hospitalisations. However, variant results indicate that further investigations are needed, aiming at confirming the beneficial effects of albumin, clarifying its optimal dosage and administration schedule and identify patients who would benefit most from long-term albumin administration.Keywords
This publication has 92 references indexed in Scilit:
- Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF trialHepatology, 2012
- Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortalityHepatology, 2009
- Ammonia impairs neutrophil phagocytic function in liver diseaseHepatology, 2008
- Mechanisms of extrahepatic vasodilation in portal hypertensionGut, 2008
- Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studiesJournal of Hepatology, 2006
- A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitisHepatology, 2005
- The Major Histocompatibility Complex–related Fc Receptor for IgG (FcRn) Binds Albumin and Prolongs Its LifespanThe Journal of Experimental Medicine, 2003
- Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangementHepatology, 2003
- Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albuminJournal of Molecular Biology, 2000
- Abnormalities of neutrophil phagocytosis, intracellular killing and metabolic activity in alcoholic cirrhosis and hepatitisHepatology, 1986